‘Remarkable’ Responses in Rare Skin Cancer

In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC – a rare, aggressive type of skin cancer – the clinical response rate was similar to that typically seen with standard chemotherapy, but the duration of the response appeared to be markedly longer.

http://snip.ly/3vpko?utm_content=buffer200bc&utm_medium=social&utm_source=thecenternews.com&utm_campaign=buffer#http://www.eurekalert.org/pub_releases/2016-04/fhcr-mcc041516.php